Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis

Nature Reviews Clinical Oncology, Published online: 11 April 2023; doi:10.1038/s41571-023-00762-1Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research